Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: A real-world study.

Publication date: Jul 09, 2023

Palmoplantar pustulosis (PPP), a chronic and stubborn skin disease, is mainly confined to the palms or/and soles, making it possible for localized use of therapeutic antibodies. In this real-world prospective cohort study, 8 patients with PPP received palms/soles injections of ixekizumab (0. 8 mg in 0. 1 ml) every 2 to 8 weeks due to the COVID-19 pandemic. The treatment endpoint was a 75% improvement from baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI 75). At week 8, 75%, 50% and 12. 5% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. At week 12, 100%, 67. 5% and 25% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. This is the first study to evaluate the efficacy and safety of local injection of micro-dose ixekizumab for PPP in real clinical practice. A high proportion of patients rapidly achieved PPPASI 75, and maintained long-term efficacy with satisfactory safety.

Concepts Keywords
8weeks Anti-interleukin-17A antibody
Antibodies Ixekizumab
Palmoplantar Local injection
Pandemic micro-dose
Palmoplantar pustular


Type Source Name
disease VO injection
disease VO dose
disease MESH skin disease
drug DRUGBANK Ixekizumab
disease MESH COVID-19 pandemic
disease MESH Psoriasis

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *